{"id":941001,"date":"2026-03-02T08:22:18","date_gmt":"2026-03-02T13:22:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/"},"modified":"2026-03-02T08:22:18","modified_gmt":"2026-03-02T13:22:18","slug":"apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/","title":{"rendered":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., March  02, 2026  (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company\u2019s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.\u00a0<\/p>\n<p>\u201cWe are thrilled to welcome\u00a0Mikael to the Apellis Board of Directors,\u201d said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. \u201cMikael is\u00a0a proven\u00a0industry leader\u00a0with\u00a0deep\u00a0experience developing\u00a0innovative\u00a0medicines.\u00a0His\u00a0strategic\u00a0insight and\u00a0expertise will be a\u00a0valuable\u00a0asset\u00a0as we\u00a0continue to\u00a0advance our robust complement pipeline.\u201d<\/p>\n<p>Dr. Dolsten brings\u00a0extensive\u00a0pharmaceutical research and development experience to the Apellis Board. Prior to\u00a0Pfizer, Dr. Dolsten held senior research and leadership positions at Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, Pharmacia, and\u00a0Upjohn.\u00a0<\/p>\n<p>He currently serves on the boards of directors of public companies Agilent Technologies, Inc., and Rocket Pharmaceuticals. \u00a0He\u00a0is chairman or board director\u00a0of several private companies including\u00a0Orbis Medicines,\u00a0Orogen Therapeutics, Quarry Thera, ChAi Discovery,\u00a0Enveda Bio and Arbor Biotechnologies. Dr. Dolsten is also a senior advisor\u00a0for financially oriented business groups\u00a0such as\u00a0Blackstone, GV (Google Ventures), Bain &amp; Company, Sutter Hill Ventures, Canaan Partners and Formation Bio.<\/p>\n<p>\u201cApellis has\u00a0established\u00a0itself\u00a0as the leading complement company, and I am excited\u00a0to join\u00a0its\u00a0Board of\u00a0Directors,\u201d said\u00a0Dr. Dolsten. \u201cComplement\u00a0therapies\u00a0have\u00a0tremendous potential to help patients\u00a0across\u00a0a wide range of serious conditions,\u00a0and\u00a0I look forward to\u00a0bringing\u00a0my\u00a0R&amp;D\u00a0and broad global biopharmaceutical\u00a0experience\u00a0to\u00a0help\u00a0advance Apellis\u2019 highly innovative\u00a0pipeline.\u201d<\/p>\n<p>Dr. Dolsten has published approximately 160 scientific articles and book reviews.\u00a0He\u00a0earned his M.D. and Ph.D. from Lund University in Sweden, where he also served as an\u00a0adjunct\u00a0professor.<\/p>\n<p>\n        <strong>About Apellis<\/strong>\u00a0<br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TK0yggbt7aA1d8RjyNUSetkQ6nTYGNO_mah_3rez-tlTwbtQwGd6iMbCHLWh_H06LSJub3axMStaQ-_1j_yN5n31o_X2M_kPkfgQpzRXdTd7diydvU-sYjye-8P2uTKZh-nPox4zTDVyYy6uQN6LIIF0_NTOgYLlRubB75dbw6VyuyiifyJr_TITBGBTSQMdSEM97plxyrd5LtBRi9VoVyM14k6dqCcgMP8NfCYCmgM7cm0tpSviyk7vXOrSVwY9OB0mxPKfWZDWbVgvv7f6mDIDm8hjDwxoJYwpxS3T9Absu4RlvN5BLYUtdvkk8YHFB-Osb7uqpHsw0XzMf1jLz5dlfbCDloqPXuzPTj_C_M0dH4uxueF061MLvGKqRPAMFcL61_pQ8l7nf8EClLM1c3MnIVblbfFfnLk7dNX5UD3T7gt3nzkl4XiV3nEQ8Lov\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/apellis.com<\/u><\/a>\u00a0or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ygZbl9plBkaXUp_FwJFKwkYGLcZ9Tg6_iToQXKZOX9GOv3bLUIO-aLWuIzPQcslHJlGVQkAvThazMGrgc_cHHeK61d3OpuLzf5wNXTfLmYs=\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U0tBxObOnuIhSC6em8sgGaPA3UMCOwV4vJDopV5YVAGy2xHYFnxgiNxf8gZJRsMb7gChXcuLCdDTU-gXn6kv8Q==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Apellis<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>Forward-Looking<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>Statement<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the \u201cRisk Factors\u201d section of Apellis\u2019 Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Media:<\/strong>\u00a0<br \/>Tracy Vineis\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P6NzhHc4HOb-CTcHUtPm-8z5ZQbNo_Xrq7IVvkFI1ZA5Li_KFABBWZXST-NX7ONAog9qGMw5H2FMnaz5FOLx16xDWJbZzmktkLM9CvYRhmU=\" rel=\"nofollow\" target=\"_blank\"><u>media@apellis.com<\/u><\/a>\u00a0<br \/>617.420.4839\u00a0<\/p>\n<p>\n        <strong>Investors:\u202f<\/strong>\u00a0<br \/>Eva Stroynowski\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K-zIKnVLOJu1BsRRDbJ3UWsyeGo79yoHWG_B5MYgVvQC-hkTtE4rnSNaRWh-Vjt4go5eQEGb-oIv8v5z1ENf3w==\" rel=\"nofollow\" target=\"_blank\">ir@apellis.com<\/a><br \/>617.938.6229<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzBlZDMyODAtMDgxNS00YTQ3LThmMWMtYjk0NDE5ODU0N2YyLTEwMzE1OTgtMjAyNi0wMy0wMi1lbg==\/tiny\/Apellis-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company\u2019s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.\u00a0 \u201cWe are thrilled to welcome\u00a0Mikael to the Apellis Board of Directors,\u201d said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. \u201cMikael is\u00a0a proven\u00a0industry leader\u00a0with\u00a0deep\u00a0experience developing\u00a0innovative\u00a0medicines.\u00a0His\u00a0strategic\u00a0insight and\u00a0expertise will be a\u00a0valuable\u00a0asset\u00a0as we\u00a0continue to\u00a0advance our robust complement pipeline.\u201d Dr. Dolsten brings\u00a0extensive\u00a0pharmaceutical research and development experience to the Apellis Board. Prior to\u00a0Pfizer, Dr. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company\u2019s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.\u00a0 \u201cWe are thrilled to welcome\u00a0Mikael to the Apellis Board of Directors,\u201d said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. \u201cMikael is\u00a0a proven\u00a0industry leader\u00a0with\u00a0deep\u00a0experience developing\u00a0innovative\u00a0medicines.\u00a0His\u00a0strategic\u00a0insight and\u00a0expertise will be a\u00a0valuable\u00a0asset\u00a0as we\u00a0continue to\u00a0advance our robust complement pipeline.\u201d Dr. Dolsten brings\u00a0extensive\u00a0pharmaceutical research and development experience to the Apellis Board. Prior to\u00a0Pfizer, Dr. &hellip; Continue reading &quot;Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T13:22:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors\",\"datePublished\":\"2026-03-02T13:22:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/\"},\"wordCount\":633,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/\",\"name\":\"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\",\"datePublished\":\"2026-03-02T13:22:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk","og_description":"WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company\u2019s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.\u00a0 \u201cWe are thrilled to welcome\u00a0Mikael to the Apellis Board of Directors,\u201d said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. \u201cMikael is\u00a0a proven\u00a0industry leader\u00a0with\u00a0deep\u00a0experience developing\u00a0innovative\u00a0medicines.\u00a0His\u00a0strategic\u00a0insight and\u00a0expertise will be a\u00a0valuable\u00a0asset\u00a0as we\u00a0continue to\u00a0advance our robust complement pipeline.\u201d Dr. Dolsten brings\u00a0extensive\u00a0pharmaceutical research and development experience to the Apellis Board. Prior to\u00a0Pfizer, Dr. &hellip; Continue reading \"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T13:22:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors","datePublished":"2026-03-02T13:22:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/"},"wordCount":633,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/","name":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=","datePublished":"2026-03-02T13:22:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzEzMSM3NDU5NjMxIzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}